Abstract
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Anti-Infective Agents
Title: Recurrent Hepatitis C After Liver Transplantation
Volume: 10 Issue: 1
Author(s): Sandeep Mukherjee
Affiliation:
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Abstract: Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Export Options
About this article
Cite this article as:
Mukherjee Sandeep, Recurrent Hepatitis C After Liver Transplantation, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010034
DOI https://dx.doi.org/10.2174/2211362611201010034 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design HIF-1 Signaling in Drug Resistance to Chemotherapy
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Current Topics in Medicinal Chemistry Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Erythropoietin in Cancer: An Update
Current Molecular Medicine Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Current Pharmaceutical Design Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry